Perspective of tumor heterogeneity for treatments of intrahepatic cholangiocarcinoma with intrahepatic lithiasis

Abstract

The heterogeneity of tumors results in significantly distinct biological characteristics of intrahepatic cholangiocarcinoma (ICC) caused by different etiologies. Among them, ICC caused by intrahepatic lithiasis (IHL-ICC) presents challenges in early detection, tumor staging, and surgical treatment, and has the poorest prognosis among all etiologies of ICC patients. Thus, it is essential to focus on early assessment of the possibility of developing ICC, prompt intervention of intrahepatic lithiasis, anatomical resection of hepatic parenchyma corresponding to the branch of the intrahepatic bile duct undergoing cancerous transformation, and enhanced postoperative follow-up of hepatolithiasis and ICC for IHL-ICC patients. These interventions are crucial to improve the clinical outcomes and overall survival of IHL-ICC patients.

Keywords

Intrahepatic cholangiocarcinoma / heterogeneity / etiology / intrahepatic lithiasis / early diagnosis / treatment / prognosis

References

[1] Zhang H,Wu M.Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management.Cancer Lett2016;379:198-205

[2] Li Q,Su J.Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study.BMC Cancer2022;22:329 PMCID:PMC8962079

[3] Zhang XF,Bagante F.Implications of intrahepatic cholangiocarcinoma etiology on recurrence and prognosis after curative-intent resection: a multi-institutional study.World J Surg2018;42:849-57

[4] Wang Q,Lei Z.Prognosis of intrahepatic cholangiocarcinomas with hbv infection is better than those with hepatolithiasis after R0 liver resection: a propensity score matching analysis.Ann Surg Oncol2017;24:1579-87

[5] Amin MB. American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. Eight edition. Chicago, IL: American Joint Committee on Cancer, Springer; 2017. xvii 1024.

[6] Weber SM,O'Reilly EM,Miyazaki M.Intrahepatic cholangiocarcinoma: expert consensus statement.HPB2015;17:669-80 PMCID:PMC4527852

[7] Kubo S,Asaoka Y.Liver cancer study group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma.Liver Cancer2022;11:290-314 PMCID:PMC9294959

[8] Zhou H,Zhou D.Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis.Eur J Cancer2010;46:1056-61

[9] Liau JY,Yuan RH,Lee HJ.Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.Mod Pathol2014;27:1163-73

[10] Wang XW.The biological and clinical challenge of liver cancer heterogeneity.Hepat Oncol2014;1:349-53 PMCID:PMC6096446

[11] Shen X,Jin X.Development and validation of a machine learning-based nomogram for prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis.Hepatobiliary Surg Nutr2021;10:749-65 PMCID:PMC8683924

[12] Bao F,Chen H,Xu Z.Diagnosis biomarkers of cholangiocarcinoma in human bile: an evidence-based study.Cancers2022;14:3921 PMCID:PMC9406189

[13] Liu XF,Sui LL.Cholangiocarcinoma: present status and molecular aspects of diagnosis.Oncol Res2014;22:177-83 PMCID:PMC7838449

[14] Sirica AE,Groopman JD.Intrahepatic cholangiocarcinoma: continuing challenges and translational advances.Hepatology2019;69:1803-15 PMCID:PMC6433548